← back to search

Yanming Zhang

Shenyang Jianzhu University · US
Area of research
Hematology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Acute Myeloid Leukemia Research, Multiple Myeloma Research and Treatments, Acute Lymphoblastic Leukemia research, and Cancer Genomics and Diagnostics.
h-index
37
citations
6,430
works
332
NIH funding
primary concept
Medicine
email

Recent publications

Evaporation‐Induced Composition Evolution in Metal Additive Manufacturing (Adv. Funct. Mater. 7/2025)
Advanced Functional Materials 2025cited by 6position: middledoi
Association of Ticagrelor Metabolic SNPs With Adverse Drug Reactions in Patients With Acute Coronary Syndrome.
2025cited by 2position: contributordoi
Impact of DUSP22 and TP63 rearrangements in patients with ALK-negative ALCL treated with frontline BV-CH(E)P
Blood 2025cited by 0position: middledoi
Evaporation‐Induced Composition Evolution in Metal Additive Manufacturing
Advanced Functional Materials 2024cited by 20position: middledoi
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma
Blood 2024cited by 15position: middledoi
Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple Myeloma
bioRxiv (Cold Spring Harbor Laboratory) 2024cited by 1position: middledoi
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens
Nature Cancer 2023cited by 51position: middledoi
Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures
Blood 2023cited by 37position: middledoi
Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing
Nature Communications 2023cited by 27position: middledoi
S115: CONSOLIDATION WITH BLINATUMOMAB IMPROVES OVERALL AND RELAPSE-FREE SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: IMPACT OF AGE AND MRD LEVEL IN ECOG-ACRIN E1910
HemaSphere 2023cited by 17position: middledoi
Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial
Blood 2023cited by 14position: middledoi
Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial
Blood 2022cited by 75position: middledoi
Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia
American Journal of Hematology 2022cited by 24position: middledoi
Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling
Leukemia Research 2022cited by 8position: middledoi
Efficacy of Moxibustion Smoke for Stage 1 Post-Stroke Shoulder-Hand Syndrome: Protocol for a Multi-Center, Single-Blind Randomized Sham-Controlled Trial [Letter]
Dove Medical Press (Taylor and Francis Group) 2022cited by 0position: middle
Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities
Nature Communications 2021cited by 129position: middledoi
Molecular classification improves risk assessment in adult <i>BCR-ABL1–</i>negative B-ALL
Blood 2021cited by 116position: middledoi
Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis
Nature Communications 2021cited by 94position: middledoi
Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas
Modern Pathology 2021cited by 76position: middledoi
Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma
Nature Communications 2021cited by 51position: middledoi
High resolution copy number inference in cancer using short-molecule nanopore sequencing
Nucleic Acids Research 2021cited by 24position: middledoi
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Nature Medicine 2021cited by 9position: middledoi
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Nature Medicine 2021cited by 4position: middledoi
Inefficacy of Immunosuppressive Therapy for Severe Aplastic Anemia Progressing From Non-SAA: Improved Outcome After Allogeneic Hematopoietic Stem Cell Transplantation
Frontiers in Oncology 2021cited by 4position: middledoi
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Nature Medicine 2020cited by 628position: middledoi
Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms
Blood Advances 2020cited by 107position: middledoi
Accelerated single cell seeding in relapsed multiple myeloma
Nature Communications 2020cited by 80position: middledoi
Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade
Cell Death and Disease 2020cited by 57position: middledoi
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
Nature Genetics 2019cited by 611position: middledoi
Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models
Nature Communications 2018cited by 113position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Martin S. Tallman · Midwestern University3 papers (2016–2022)Selina M. Luger · Dana-Farber Cancer Institute3 papers (2016–2022)Ross L. Levine · Leukemia and Lymphoma Society3 papers (2016–2022)Hillard M. Lazarus · Case Western Reserve University3 papers (2016–2022)Elisabeth Paietta · Dana-Farber Cancer Institute3 papers (2016–2022)Mark R. Litzow · Mayo Clinic3 papers (2016–2022)Zhuoxin Sun · Hebei Medical University3 papers (2016–2022)Timour Baslan · University of Pennsylvania2 papers (2021–2022)Wentao Yan · University of Shanghai for Science and Technology2 papers (2024–2025)Guochen Peng · National University of Singapore2 papers (2024–2025)Ahmet Doǧan · Kettering Medical Center2 papers (2020–2021)Scott W. Lowe · Memorial Sloan Kettering Cancer Center2 papers (2021–2022)Shiwei Wu · National University of Singapore2 papers (2024–2025)Keith W. Pratz · Abramson Cancer Center2 papers (2016–2022)Lu Wang · National University of Singapore2 papers (2024–2025)Zixu Guo · National University of Singapore2 papers (2024–2025)Daniel A. Arber · University of Illinois Chicago2 papers (2016–2022)Jacob M. Rowe · University of Maryland, College Park2 papers (2016–2022) · 1 papers (2025–2025)Benjamin Diamond · University of Miami1 papers (2021–2021)